Biological therapy for rheumatoid arthritis: where are we now?

Abstract	Since the introduction of targeted biological therapies, the implications of a new diagnosis of rheumatoid arthritis have changed dramatically. There are now several therapeutic options available for these patients and the target of treatment - remission - is now a realistic goal.
Authors	Sarah C Horton, Paul Emery
Journal	British journal of hospital medicine (London, England : 2005) (Br J Hosp Med (Lond)) Vol. 73 Issue 1 Pg. 12-8 (Jan 2012) ISSN: 1750-8460 [Print] England
PMID	22241404 (Publication Type: Journal Article, Review)
Chemical References	Antibodies, Monoclonal, Humanized Antibodies, Monoclonal, Murine-Derived Antirheumatic Agents Immunoconjugates Tumor Necrosis Factor-alpha Rituximab Abatacept tocilizumab Methotrexate
Topics	Abatacept Antibodies, Monoclonal, Humanized (therapeutic use) Antibodies, Monoclonal, Murine-Derived (therapeutic use) Antirheumatic Agents (administration & dosage, adverse effects, therapeutic use) Arthritis, Rheumatoid (drug therapy) Humans Immunoconjugates (therapeutic use) Immunotherapy Methotrexate (therapeutic use) Molecular Targeted Therapy Prognosis Randomized Controlled Trials as Topic Remission Induction Rituximab Tumor Necrosis Factor-alpha (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!